Relapsing-remitting multiple sclerosis is a neurological condition that affects roughly 85% of people living with multiple sclerosis. Treatment strategies focus on managing flare-ups, reducing the frequency of relapses, and helping people maintain quality of life through both established medications and innovative therapies currently being tested in research settings.

Navigating Treatment Options After Diagnosis

When someone receives a diagnosis of relapsing-remitting multiple sclerosis (RRMS), the primary goal of treatment is to reduce how often relapses occur and to lessen their severity when they do happen. This form of multiple sclerosis follows a pattern where symptoms flare up during what doctors call relapses or exacerbations, then improve or disappear during remission periods. Treatment aims to extend those remission phases and prevent new damage to the nervous system^[1].

The approach to treating RRMS depends heavily on how active the disease is at the time of diagnosis, which symptoms appear during relapses, and how each person responds to different medications. Some people experience complete recovery between relapses, while others have lingering symptoms that require ongoing management. Healthcare teams consider these individual patterns when deciding which treatments to recommend^[4].

Modern medicine offers both standard treatments that have been used for years and newer therapies that are being studied in clinical trials. Standard treatments are approved by medical regulatory bodies and have established track records of safety and effectiveness. Meanwhile, researchers continue investigating new molecules and treatment approaches that might offer even better outcomes for people living with RRMS^[9].

Starting treatment early often makes a meaningful difference. When therapy begins soon after diagnosis, it can help prevent the accumulation of damage to the myelin sheath—the protective covering around nerve fibers in the brain and spinal cord. This early intervention may slow the progression of disability and help people maintain their independence longer^[13].

Standard Medical Treatments for Managing Relapses

When someone with RRMS experiences a relapse lasting at least 24 hours, doctors typically treat it with high doses of corticosteroids. These powerful medications work by reducing inflammation in the central nervous system. The most commonly prescribed corticosteroid is methylprednisolone, which is given through an intravenous line over three to five days. Some people receive an equivalent high dose by mouth instead^[8].

Corticosteroids help shorten the duration of a relapse and can lessen its severity, making symptoms more manageable. However, they don’t change the long-term course of the disease or prevent future relapses. After the high-dose treatment, doctors sometimes prescribe prednisone in pill form, gradually reducing the dose over one to two weeks to ease the person off the medication^[8].

For people who cannot tolerate corticosteroids or who haven’t responded well to them in the past, another option exists. Adrenocorticotropic hormone (ACTH) preparations, available under brand names like Acthar Gel and Purified Cortrophin Gel, work similarly to corticosteroids. These medications are approved specifically for treating MS relapses and are given once daily^[8].

It’s important to understand that not every relapse requires corticosteroid treatment. Doctors typically reserve these medications for moderate to severe flare-ups that significantly affect daily functioning. Mild relapses may not be treated with steroids, allowing the body to recover on its own during the natural remission phase^[12].

Disease-Modifying Therapies: Long-Term Prevention

Beyond treating individual relapses, the cornerstone of RRMS management involves disease-modifying therapies (DMTs) or disease-modifying drugs (DMDs). These medications are taken regularly—not just during relapses—to reduce how often relapses occur and to slow the progression of the disease. They work by modifying how the immune system functions, preventing it from attacking the myelin sheath^[11].

One of the oldest and most frequently used categories of DMTs is interferon beta. These medications come in several forms, including interferon beta-1a (available as Avonex or Rebif) and interferon beta-1b (Betaseron). They’re given by injection, either into the muscle or under the skin, at regular intervals. Interferons help regulate immune system activity, though the exact way they work in MS isn’t completely understood. A longer-acting version called peginterferon beta-1a (Plegridy) requires less frequent injections^[9][11].

Another injectable medication is glatiramer acetate (Copaxone), which works differently from interferons. It’s thought to block immune system attacks on myelin by mimicking certain proteins. People typically inject it daily or several times per week. This medication has been studied extensively and is considered a standard option for RRMS^[9][11].

More recently, ofatumumab (Kesimpta) has become available as a self-injectable medication. Unlike interferons and glatiramer, ofatumumab is a type of antibody that targets specific immune cells called B cells, depleting them from the bloodstream. This newer medication has shown impressive effectiveness in preventing relapses^[13][18].

Several DMTs come in pill form, which some people find more convenient than injections. Dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), and monomethyl fumarate (Bafiertam) are related medications taken twice daily. They appear to reduce inflammation and may protect nerve cells. Fingolimod (Gilenya), siponimod (Mayzent), ozanimod (Zeposia), and ponesimod (Ponvory) work by trapping certain immune cells in lymph nodes so they can’t travel to the brain and spinal cord. Teriflunomide (Aubagio) and cladribine (Mavenclad) reduce the number of immune cells in different ways^[11].

Some highly effective DMTs are given through an intravenous line at a clinic or hospital. Natalizumab (Tysabri) is infused monthly and prevents immune cells from crossing into the brain and spinal cord. Ocrelizumab (Ocrevus) and its high-concentration formulation (Ocrevus Zunvovo) target and deplete B cells; infusions occur every six months after initial loading doses. Alemtuzumab (Lemtrada) is given as two courses of daily infusions, separated by a year, and works by depleting immune cells that are then slowly rebuilt^[11][13].

Each of these medications carries different side effects and monitoring requirements. Injectable medications may cause injection site reactions or flu-like symptoms. Oral medications can affect the liver, increase infection risk, or cause digestive issues. Infusion therapies require careful monitoring for serious but rare complications. Doctors work closely with each person to choose the medication that best balances effectiveness against potential risks based on individual health factors^[9].

Supportive Treatments for Persistent Symptoms

Even with disease-modifying therapy, many people with RRMS experience ongoing symptoms that need management. Muscle stiffness or spasticity often responds to a combination of physical therapy, regular stretching programs, and medications. In severe cases, doctors may recommend Botox injections into affected muscles to reduce tightness and improve mobility. Physical therapists play a crucial role in designing exercise programs that maintain strength without causing overheating, which can temporarily worsen symptoms^[1][10].

Fatigue, one of the most common and challenging symptoms, requires a multifaceted approach. This includes pacing activities throughout the day, prioritizing rest, and sometimes using medications that promote wakefulness. Occupational therapists can suggest energy-conservation techniques and adaptive equipment that make daily tasks less exhausting^[1].

Bladder and bowel problems affect many people with RRMS. Treatments range from pelvic floor exercises and timed voiding schedules to medications that help control urgency or retain urine. For some people, intermittent catheterization becomes necessary. Dietary modifications and medications can address constipation or bowel urgency^[1].

Cognitive difficulties—often described as “brain fog”—may improve with cognitive rehabilitation therapy. This specialized form of therapy teaches strategies for managing memory problems and concentration difficulties. Some people benefit from medications used for other conditions that affect thinking^[1][10].

Innovative Therapies Being Tested in Clinical Trials

Researchers worldwide are continuously investigating new treatment approaches for RRMS through clinical trials. These studies test whether experimental medications are safe and effective before they become available to everyone. Clinical trials typically progress through three phases: Phase I focuses on safety in small groups, Phase II examines effectiveness in larger groups, and Phase III compares the new treatment directly with existing standard treatments^[9].

One of the most exciting recent developments involves medications that deplete B cells more effectively. While ocrelizumab and ofatumumab have already received approval, researchers are studying whether even more targeted approaches to B cell depletion might offer better outcomes with fewer side effects. These studies are examining different antibodies that attach to specific markers on B cells^[13][18].

Some clinical trials are investigating whether existing medications used at different doses or in new combinations might improve results. For example, researchers are testing whether combining certain oral medications with injectable therapies provides better relapse prevention than either treatment alone. Other studies examine whether adjusting the timing or frequency of infusion therapies changes their effectiveness^[9].

Scientists are also exploring treatments that might help repair existing damage to the myelin sheath—something current medications don’t do. These remyelination or neuroprotection therapies aim to restore the protective covering around nerve fibers rather than just preventing new damage. Several molecules that promote myelin repair are in various stages of clinical testing, though none have yet proven effective enough for approval^[9].

Researchers are investigating whether stem cell therapies might benefit people with RRMS. Autologous hematopoietic stem cell transplantation (AHSCT) involves collecting a person’s own blood-forming stem cells, then using strong medications to destroy their existing immune system before returning the stem cells to rebuild a new immune system. This intensive treatment is being studied for people with highly active RRMS who haven’t responded to standard medications. Early results have been promising, but the procedure carries significant risks and requires extensive hospitalization^[9].

Another research direction involves developing medications that target specific molecular pathways involved in MS inflammation. Scientists have identified various proteins, enzymes, and receptors that play roles in immune system attacks on myelin. Clinical trials are testing whether blocking these specific targets can prevent relapses without suppressing the entire immune system. This more targeted approach might reduce side effects compared to broader immune suppression^[9].

Some experimental therapies focus on immune tolerance—teaching the immune system to stop attacking myelin without weakening its ability to fight infections. These approaches include vaccines using myelin proteins, medications that modify how immune cells respond to myelin, and techniques that remove harmful immune cells from the blood. While conceptually promising, most of these approaches are still in early research phases^[9].

Clinical trials for RRMS treatments take place in medical centers across the United States, Europe, and other regions. Eligibility for specific trials depends on factors like disease activity, previous treatments, other health conditions, and age. People interested in clinical trial participation can discuss options with their neurologist or search clinical trial registries to find studies accepting participants^[9].

Monitoring Treatment Effectiveness

Once treatment begins, regular monitoring helps determine whether it’s working effectively. Doctors typically schedule follow-up appointments every few months to ask about new symptoms, relapses, and medication side effects. They perform neurological examinations to check for changes in strength, coordination, vision, and sensation^[4].

Magnetic resonance imaging (MRI) scans play a crucial role in monitoring RRMS. These scans create detailed images of the brain and spinal cord, revealing areas of inflammation or damage. Doctors can see new lesions forming even when a person doesn’t experience noticeable symptoms—these are called “silent relapses.” Regular MRI monitoring, typically yearly or every six months initially, helps doctors detect disease activity that might not be apparent otherwise^[13][18].

If MRI scans show new lesions or if relapses continue despite treatment, doctors may recommend switching to a different medication. Finding the right treatment sometimes requires trying several options. The goal is to achieve what doctors call “no evidence of disease activity” or NEDA—meaning no relapses, no new lesions on MRI, and no worsening of disability^[13].

Blood tests are necessary when taking certain DMTs to monitor for side effects. Some medications can affect liver function, blood cell counts, or kidney function. Regular blood draws help catch these problems early before they become serious. Doctors adjust medication doses or switch treatments if concerning changes appear in blood test results^[9].

Treatment Considerations for Special Populations

Treatment decisions become more complex for pregnant women or those planning pregnancy. Most disease-modifying therapies should not be used during pregnancy because they could potentially harm the developing baby. However, RRMS often becomes less active during pregnancy naturally, particularly in the second and third trimesters. Many women work with their doctors to stop treatment before conceiving, then restart after delivery and breastfeeding. Some newer medications may be safer options during pregnancy, and research continues in this area^[12].

For women who are breastfeeding, treatment choices also require careful consideration. Some medications pass into breast milk and could affect the nursing infant, while others appear safer. Women and their healthcare teams weigh the benefits of continued breastfeeding against the benefits of restarting disease-modifying therapy, making individualized decisions based on disease activity and personal preferences^[12].

Children and adolescents diagnosed with RRMS need special consideration. While the disease behaves similarly in younger people, treatment choices may differ. Not all medications have been studied extensively in children, and growing bodies may respond differently. Pediatric neurologists specializing in MS work closely with families to choose appropriate treatments while considering the unique needs of developing brains and bodies^[12].

Older adults with RRMS face different considerations. As people age, their immune systems naturally become less active, which might reduce MS activity but also increases vulnerability to infections from immune-suppressing medications. Older individuals often have other health conditions requiring their own medications, raising concerns about drug interactions. Doctors balance the benefits of aggressive MS treatment against the increased risks in older populations^[9].

The Importance of Lifestyle and Wellness

While medications form the foundation of RRMS treatment, lifestyle choices significantly influence disease course and quality of life. Regular exercise has proven benefits, including improved strength, better mood, reduced fatigue, and possibly slower disease progression. Exercise programs should be tailored to individual abilities and should avoid overheating, which can temporarily worsen symptoms. Activities like swimming, walking, and gentle yoga are often well-tolerated^[16].

Diet appears to play a role in MS management, though research hasn’t identified one perfect eating plan. Evidence suggests that diets rich in fruits, vegetables, and whole grains while limiting processed foods and animal fats may benefit people with MS. Some research points to the Mediterranean diet—emphasizing fish, nuts, olive oil, and vegetables while limiting red meat—as potentially protective for the brain and spinal cord^[7][16].

Maintaining adequate vitamin D levels deserves special attention. People with higher vitamin D levels may have lower risk of developing MS and possibly fewer relapses. Vitamin D comes from sunlight exposure, fatty fish, fortified milk, and supplements. Doctors can check vitamin D levels through blood tests and recommend supplementation if needed^[1][16].

Avoiding tobacco is crucial. Smoking not only increases the risk of developing MS but also speeds disease progression in people who already have it. People with MS who smoke tend to accumulate disability faster than non-smokers. Quitting smoking can slow this progression, making smoking cessation a critical part of comprehensive MS care^[1][16].

Getting adequate, restful sleep supports both physical and mental health. Many people with MS experience sleep disturbances from symptoms like muscle spasms, pain, or frequent nighttime urination. Addressing these symptoms, practicing good sleep hygiene, and treating any underlying sleep disorders like sleep apnea can significantly improve daytime functioning and overall well-being^[16].

Managing stress is important since stress can trigger pseudo-exacerbations or worsen existing symptoms. Techniques like meditation, mindfulness, counseling, and participation in support groups help many people cope with the emotional challenges of living with a chronic condition. Mental health support should be considered an integral part of comprehensive MS care^[1][4].

Most common treatment methods

• Corticosteroid therapy for acute relapses
  • High-dose intravenous methylprednisolone given over 3-5 days to reduce inflammation during relapses
  • Oral high-dose corticosteroids as an alternative to IV administration
  • Prednisone taper following high-dose treatment to gradually discontinue steroid therapy
  • ACTH preparations (Acthar Gel, Purified Cortrophin Gel) for people who cannot tolerate standard corticosteroids
• Injectable disease-modifying therapies
  • Interferon beta-1a (Avonex, Rebif) given by intramuscular or subcutaneous injection
  • Interferon beta-1b (Betaseron) administered subcutaneously
  • Peginterferon beta-1a (Plegridy) as a longer-acting interferon option
  • Glatiramer acetate (Copaxone) injected daily or several times weekly
  • Ofatumumab (Kesimpta) as a self-injectable B-cell-depleting therapy
• Oral disease-modifying medications
  • Fumarate medications including dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), and monomethyl fumarate (Bafiertam)
  • S1P receptor modulators such as fingolimod (Gilenya), siponimod (Mayzent), ozanimod (Zeposia), and ponesimod (Ponvory)
  • Teriflunomide (Aubagio) that reduces immune cell proliferation
  • Cladribine (Mavenclad) given as two short courses of treatment
• Infusion therapies
  • Natalizumab (Tysabri) infused monthly to prevent immune cells from entering the central nervous system
  • Ocrelizumab (Ocrevus, Ocrevus Zunvovo) given every six months to deplete B cells
  • Alemtuzumab (Lemtrada) administered as two annual courses to reset the immune system
• Symptom management approaches
  • Physical therapy programs focusing on strength, flexibility, and balance
  • Medications and Botox injections for muscle spasticity and stiffness
  • Bladder management strategies including medications and behavioral techniques
  • Cognitive rehabilitation for memory and concentration difficulties
  • Fatigue management through pacing, energy conservation, and sometimes wakefulness-promoting medications
• Experimental therapies in clinical trials
  • Novel B-cell-depleting antibodies targeting specific immune cell markers
  • Remyelination therapies attempting to repair damaged myelin sheaths
  • Autologous hematopoietic stem cell transplantation for highly active disease
  • Immune tolerance approaches teaching the immune system to stop attacking myelin
  • Medications targeting specific molecular pathways in MS inflammation